BioSpace News Archive

Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient-specific knee and hip joint replacement implants designed to fit each patient’s unique anatomy, announced today that the Company has achieved the milestone of 100,000 knee joint replacement implants manufactured and sold in the U.S.

Kedrion Biopharma, an international specialist in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases, today announced that enrollment is complete in the CARES10 (Clinical Assessment of phaRmacokinetics, Efficacy, Safety of a 10% Ig) clinical study. CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics

NeoImmuneTech, Inc., a T cell-focused immunotherapeutics company, today announced the appointment of Gene Namgoong as Chief Operating Officer (COO).

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, today announced the upcoming February 6 release of its first-ever Lung Cancer Scorecard that grades individual states on policies that support access to optimal care for lung cancer patients

Profusa, a digital health company that is pioneering the next generation of personalized medicine, today announced research findings that suggest the company’s Lumee® Oxygen Platform may help improve the clinical management of patients with critical limb ischemia (CLI) who are undergoing endovascular revascularization treatment (EVT).

BIONIK Laboratories Corp. (OTCQB:BNKL) (“BIONIK”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced it has received regulatory approval in South Korea, and that its exclusive distributor Curexo secured the first sale for BIONIK’s InMotion® robotic technology in the country, out of Curexo’s existing inventory.

Hitachi Chemical Advanced Therapeutics Solutions, LLC (“HCATS”), a subsidiary of Hitachi Chemical Co., Ltd. representing Hitachi Chemical’s Regenerative Medicine Business Sector (“RMBS”) in North America, today announced the opening of its new cell and gene therapy manufacturing facility in Allendale, New Jersey.

Diverse Biotech, Inc. www.diversebiotech.com has announced it has been selected to present at the following prestigious events.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven, pharmaceutical quality cannabis extraction, distillation, and derivative products, today provided an update on its aggregate liquidity position, which supports plans for domestic and international growth, and announced it has fulfilled further Cannabis 2.0 product shipments to Canadian provincial distributors in January 2020.

Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU).